PARABLE: Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation

Sponsor

Mark Ledwidge (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT04687111

Collaborator

The Heartbeat Trust (Other)

250

Enrollment

Locations

Arms

65.8

Anticipated Duration (Months)

125

Patients Per Site

1.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure with reduced ejection fraction. In stage C HFpEF, sacubitril-valsartan has also been shown to reduce left atrial volume index measured using echocardiography over a 9 month timeframe. The PARABLE study investigates the hypothesis that sacubitril-valsartan can provide benefits in terms of left atrial structure and function as well as left ventricular structure and function in asymptomatic (stage A/B HFpEF) patients. This is a prospective, randomised, double-blind, double-dummy, phase II study design. The patient population will have hypertension and/or diabetes together with preserved ejection fraction, elevated natriuretic peptide (NP) and abnormal left atrial volume index (LAVI, > 28 mL/m2).

Condition or Disease	Intervention/Treatment	Phase
Atrial Remodeling Myocardial Dysfunction Left Ventricular Remodeling Left Ventricular Diastolic Dysfunction Hypertension Cardiovascular Morbidity Fibrosis Myocardial Inflammatory Myopathy Atrial Arrhythmia	Drug: Sacubitril-Valsartan Drug: Valsartan	Phase 2

Detailed Description

Background.

An effective prevention strategy is critical if the established epidemic of heart failure and cardiovascular disease is to be curbed. This is particularly important in the context of increasing community prevalence of stage B HFpEF and left ventricular diastolic abnormalities associated with hypertension and diabetes and requires community diagnostics and targeted preventative therapies. Individualising risk beyond the presence of established risk factors can be achieved with NP assessment. Elevated NP in a population with established cardiovascular disease defines a group more prone to cardiac dysfunction, heart failure and other cardiovascular events. This can be used to risk stratify asymptomatic populations, targeting those most likely to need intensive intervention and follow-up.

In the prospective, randomised, pragmatic St Vincent's Screening TO Prevent Heart Failure (STOP-HF) trial [Ledwidge 2013], NP-based screening and collaborative care with general practice provided a multi-faceted intervention for patients with risk factors for heart failure. This involved community NP screening, improved use of RAAS modifying therapy, collaborative care with general practice as well as cardiovascular coaching for patients with mild elevations of BNP (>50 pg/mL).The intervention reduced stage B and C heart failure, most of which was preserved ejection fraction, as well as major adverse cardiovascular events requiring hospitalisation. This first of type study, along with a second study in diabetes [Huelsmann 2013], indicates that a biomarker driven strategy based on NP screening amongst stage AB heart failure patients is feasible and has an impact on heart failure and other cardiovascular diseases. These studies have been incorporated into 2017 American Heart Association/American College of Cardiology guidelines as well as other international guideline recommendations in heart failure.

However, while successful, the STOP-HF biomarker strategy lacks a specific pharmacological intervention linked to the screening biomarker, NP. An analysis of the STOP-HF follow-up study, supports other work showing that the minor C allele of genetic variant rs198389 of the NPPB gene (in the promoter region) is associated with sustained, elevated circulating levels of BNP and reduced incidence of left ventricular dysfunction over a five-year follow up period. These data support the hypothesis that use of LCZ696 to pharmacologically raise NP could provide cardioprotection in stage A/B heart failure patients. As neprilysin degrades biologically active NP, LCZ696 increases myocardial cyclic guanosine monophosphate (cGMP) which reduces vascular and myocardial stiffness as well as hypertrophy. This could improve cardiac structure and performance. NPs also stimulate natriuresis, diuresis, vasodilation and have been shown to have anti-fibrotic and anti-sympathetic benefits, which could augment the STOP-HF preventative strategy with a specific pharmacological intervention. [Ledwidge 2103, Phelan 2012, Potter 2006, Gardiner 2007]. Atrial tissue gene expression of BNP in patients with stage B HFpEF is associated with atrial fibrosis, procollagen expression and presence of M2 monocyte-derived-macrophage marker CD163 [Watson 2020]. Further analyses of the STOP-HF follow-up study shows that BNP strongly associates with the presence of atrial cardiomyopathy, an independent predictor of new onset major adverse cardiovascular events.

Taken together, these data could support a role for sacubitril-valsartan versus valsartan alone in favourably modulating vascular compliance, cardiac structure, cardiac function as well as progression of left atrial structural and functional abnormalities amongst patients with stage B HFpEF. If left atrial structure and function is also associated with new onset major adverse cardiovascular events, the intervention could also modulate cardiovascular events. Finally, new CMRI imaging measures of cardiac function, such as CMR e' have been developed and will allow full characterisation of the cardiovascular impact of the intervention, including in subsets of patients with established atrial cardiomyopathy.

Rationale for the study

Elevated NP in an at-risk population independently identifies cardiovascular risk, which can be specifically targeted by LCZ696. In a small proportion of patients (<5%) with cardiovascular risk factors and elevated NP, significant asymptomatic LV systolic dysfunction will be present and for these RAAS modifying therapy is mandated. However, there is a larger group of patients with elevated NP who have stage B HFpEF, with or without diastolic dysfunction. These patients may have preclinical, or asymptomatic, left ventricular diastolic dysfunction (ALVDD), atrial cardiomyopathy (AC) or both and are at heightened risk for heart failure and other cardiovascular events [Watson 2020].

The increase in NP in stage B HFpEF, ALVDD and AC is likely a fibro-inflammatory signal, which in-turn contributes to tissue remodelling, vascular disease, myocardial stiffening and left ventricular dysfunction. For example, hypertension, a common risk factor for ALVDD, is associated with an adverse accumulation of fibrous tissue and studies have demonstrated a strong relationship between ventricular stiffness, myocardial collagen content and plasma levels of myocardial collagen turnover markers [Hogg 2004, Querejeta 2004]. Cardiac inflammation, fibrosis and hypertrophy drive the pathophysiology [Gardiner 2007, Martos 2007] associated with vascular disease, myocardial stiffening, and left atrial as well as left ventricular dysfunction. [Phelan 2012, Jannuzzi 2019] Interrupting this pathophysiological process at an early stage before the development of ventricular dysfunction may prevent or slow development to heart failure and also have an impact on the development of other cardiovascular events driven by this pathophysiological process. This may be particularly important for prevention of the development of a sub-type of stage C HFpEF characterised by older age, elevated LAVI, atrial fibrillation and chronic kidney disease, which puts patients at very high risk adverse outcome [Shah 2015]. Importantly, there is currently no specific disease modifying therapy for these patients, beyond conventional risk factor control.

Accordingly, suppressing the RAAS will reduce the pro-fibrotic impact of angiotensin II. Addition of sacubitril, which reduces degradation of endogenous, cardio-protective NPs, could reduce pulse pressure, myocardial stiffness and augment the beneficial anti-inflammatory and anti-fibrotic effects of NPs beyond conventional RAAS modifying therapy. The latter may be mediated through impacts on the innate immune system, fibro-inflammation and monocyte-derived-macrophages in the myocardium [Watson 2020].

Several studies have shown that the interplay between the myocardium and extracellular matrix (ECM) can now be evaluated via analysis of serum samples of markers of collagen turnover. [Martos 2007, Querejeta 2007] Altered serum levels of collagen markers (e.g. Collagen 1A1) and matrix metalloproteinase (e.g. MMP-2 and MMP-9) suggest increased collagen turnover associated with fibrosis in diastolic heart failure. [Martos, 2007, Ahmed 2006, Nikishimi 2006] Other biomarkers of cardiac structure and function of relevance in ALVDD/AC include Galectin 3 and ST-2, biomarkers of cardiac remodelling and tissue fibrosis. Finally, cGMP, which blunts activation pathways and diminishes hypertrophy, fibrosis, cellular toxicity, and maladaptive remodelling in the myocardium, may also be modulated by sacubitril-valsartan, not only through inhibition of breakdown of BNP, but also ANP and other vasoactive peptides [Ibrahim 2019].

In high risk patients with preserved ejection fraction, elevated LAVI reflects increased left ventricular filling pressures, fibro-inflammation and is a strong, continuous marker of diastolic dysfunction as well as future cardiovascular events. Interventions that could improve myocardial performance and reduce progression of LAVI and other structural abnormalities might also help prevent cardiac morbidity and progression to stage B/C HFpEF. Sacubitril-valsartan has been shown to modulate NP activity and reduce LAVI in comparison with valsartan in the PARAMOUNT study [Solomon 2012]. The reduction of 2.6 mL/m2 with LCZ696 compared with an increase of 0.3 mL/m2 with valsartan (p=0.007 for difference) from a baseline of 36 mL/m2 over 36 weeks appears to be clinically significant in these patients with preserved ejection fraction. However, further work is required to understand the implications of this result in stage A/B HFpEF, especially using more precisely defined myocardial structure and function with cardiac magnetic resonance imaging (cMRI). Furthermore, in the PARAGON-HF study (Solomon 2019), there was no significant benefit of sacubitril-valsartan in patients with HFpEF with respect to the primary composite outcome of hospitalisation and death. The differential effect of sacubitril-valsartan versus valsartan in relation to left ventricular ejection fraction as well as stage B versus C HFpEF requires further evaluation. No study has evaluated sacubitril-valsartan in patients with stage A/B HFpEF, elevated natriuretic peptides and abnormal LAVI.

Aim

The main aim of the PARABLE trial is to assess the impact of sacubitril-valsartan versus valsartan alone on structural, functional and biochemical abnormalities of the myocardium in an asymptomatic cohort with preserved ejection fraction, cardiovascular risk factors, abnormal LAVI and elevated NP (brain type natriuretic peptide [BNP] and/or N-terminal of the prohormone BNP [NT-proBNP]).

PARABLE tests the hypothesis that sacubitril-valsartan versus valsartan alone would result in beneficial effects on atrial and ventricular structure and function, thereby preventing progression of cardiac abnormalities in stage B HFpEF.

Study Design

Study Type:

Interventional

Actual Enrollment :

250 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Randomised, prospective, active comparator, double blind, double dummy, controlled trial.Randomised, prospective, active comparator, double blind, double dummy, controlled trial.

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description:

Double-blind, double-dummy.

Primary Purpose:

Prevention

Official Title:

A Randomised, Controlled, Double-blind, Double-dummy, Clinical Trial Comparing Sacubitril-Valsartan Versus Valsartan in Asymptomatic, Stage A/B HFpEF Patients With Elevated Natriuretic Peptide and Abnormal LAVI. (Previously NCT02682719)

Actual Study Start Date :

Dec 16, 2015

Anticipated Primary Completion Date :

Jun 11, 2021

Anticipated Study Completion Date :

Jun 11, 2021

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Control Valsartan 40mg bid titrated to maximum dose of 160mg bid	Drug: Valsartan Valsartan is an Angiotensin Receptor Blocker
Experimental: Intervention Sacubitril/Valsartan 50mg bid titrated to maximum dose of 200mg bid	Drug: Sacubitril-Valsartan Sacubitril-Valsartan is an Angiotensin Receptor blocker and Neprilysin Inhibitor Other Names: LCZ696 Entresto

Arm

Intervention/Treatment

Active Comparator: Control

Valsartan 40mg bid titrated to maximum dose of 160mg bid

Drug: Valsartan

Valsartan is an Angiotensin Receptor Blocker

Experimental: Intervention

Sacubitril/Valsartan 50mg bid titrated to maximum dose of 200mg bid

Drug: Sacubitril-Valsartan

Sacubitril-Valsartan is an Angiotensin Receptor blocker and Neprilysin Inhibitor

Other Names:

LCZ696

Entresto

Outcome Measures

Primary Outcome Measures

Change in Left Atrial Volume Index (LAV/BSA*) [Baseline-18 months]
Measured as left atrial volume (Simpson's method, using a stack of short axis slices across the entire left atrium) indexed to body surface area (*DuBois formula) using Cardiac Magnetic Resonance Imaging (cardiac MRI).

Secondary Outcome Measures

Change in left ventricular function (E/e') [Baseline -18 months]
Measured average E/e' using Doppler-echocardiography
Change in left atrial volume index (LAV/BSA*) [Baseline - 9 months]
Measured using Doppler Echocardiography between baseline and 9 months. (*BSA calculated using the DuBois formula)
Change in left atrial function measured as total left atrial ejection fraction (LAEF) [Baseline -18 months]
Measured as total LAEF ((LAVmax - LAVmin)/LAVmax, by cardiac MRI
Change in left atrial function measured as left atrial stroke volume index [Baseline -18 months]
Measured as left atrial stroke volume index (LAVmax - LAVmin)/BSA (measured using Du Bois formula), or LAVimax-LAVimin by cardiac MRI
Change in left ventricular structure measured as LVMi [Baseline -18 months]
Measured using left ventricular mass index (LVMi), indexed to BSA (calculated using the DuBois formula) using cardiac MRI
Change in left ventricular function (LVEF) [Baseline -18 months]
Measured as left ventricular ejection fraction (LVEF) using cardiac MRI
Change in measures of vascular compliance (pulse pressure) [Baseline -18 months]
Measured using pulse pressure calculated from 24 hour ABPM measurements
Change in natriuretic peptide biomarker profile [Baseline -18 months]
Defined as log-transformed NT-proBNP
Time to first all cardiovascular death and major adverse cardiac events (MACE) requiring hospitalisation over 18 months [Baseline - 18 months]
MACE includes arrythmia (including atrial fibrillation/flutter), transient ischaemic attack, stroke, valvular heart disease, myocardial infarction, peripheral or pulmonary thrombosis/embolus or heart failure
Change in Left Atrial Volume Index (LAVi) analysed per protocol. [Baseline - 18 months]
Measured as left atrial volume (Simpson's method, using a stack of short axis slices across the entire left atrium) indexed to body surface area (DuBois formula) using Cardiac Magnetic Resonance Imaging (cardiac MRI)

Eligibility Criteria

Criteria

Ages Eligible for Study:

40 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age > 40yrs with cardiovascular risk factor(s) including at least one of:
History of hypertension (medicated for greater than one month);
History of diabetes;
Elevated NP: Elevated NP: BNP between 20 and 280pg/ml or NT-proBNP values between 100 pg/ml and 1,000 pg/ml within 6 months prior to screening or at screening
LAVI > 28 mL/m2 obtained during Doppler Echocardiography within 6 months prior to screening or at screening
Subjects must give written informed consent to participate in the study and before any study related assessments are performed.

Exclusion Criteria:

A history of heart failure.
Asymptomatic left ventricular systolic dysfunction defined as LVEF <50% on most recent measurement.
Systolic blood pressure <100mmHg
Persistent atrial fibrillation.
History of hypersensitivity, allergy or intolerance to LCZ696, ARB or neprilysin therapy or to any of the excipients or other contraindication to their use.
Previous history of intolerance to recommended target doses for ARBs
Subjects who require treatment with both an ACE inhibitor and an ARB
Presence of haemodynamically significant mitral and /or aortic valve disease.
Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic stenosis.
Conditions that are expected to compromise survival over the study period.
Serum potassium level > 5.2 mmol/L at screening.
Severe renal insufficiency (eGFR <30 mL per minute per 1.73 m2).
Hepatic dysfunction (Any LFT > 3 times the upper limit of normal (ULN))
Concomitant use of aliskiren
History of angioedema.
History or evidence of drug or alcohol abuse within the last 12 months
Malignancy or presence of any other disease with a life expectancy of < 2 years
Women who are pregnant, breast-feeding, or women of child bearing potential not using estro-progestative oral or intra-uterine contraception or implants, or women using estro-progestative oral or intra-uterine contraception or implants but who consider stopping it during the planned duration of the study. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. (Contraception must be continued for one week following discontinuation of study drug).
Concomitant participation in other intervention trials
Participation in any investigational drug trial within one month of visit 1.
Refusal to provide informed consent
Subjects with contraindications to MRI
Brain aneurysm clip
Implanted neural stimulator
Implanted cardiac pacemaker or defibrillator
Cochlear implant
Ocular foreign body (e.g. metal shavings)
Other implanted medical devices: (e.g. Swan-Ganz catheter)
Insulin pump
Metal shrapnel or bullet.
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs, including but not limited to any of the following:
History of major gastrointestinal tract surgery including gastrectomy, gastroenterostomy, or bowel resection.
Inflammatory bowel disease during the 12 months prior to Visit 1.
Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase.
Evidence of hepatic disease as determined by any one of the following: SGOT or SGPT values exceeding 3 x ULN at Visit 1, a history of hepatic encephalopathy, a history of oesophageal varices, or a history of portocaval shunt.